Objective. To systematically review the accuracy and characteristics of different questionnaire-based PsA screening tools.
Introduction
PsA is an autoimmune and chronic musculoskeletal disorder that is associated with psoriasis of the skin [1] . Its presentation can vary from subtle manifestations to highly destructive forms. Joint pain, stiffness and swelling are the most common symptoms [2] . Similar to other arthritis-related diseases, early treatment is expected to control joint damage, which usually occurs within the first 2 years of disease [3] . Screening procedures are an important first step of early treatment.
Patients with psoriasis are an easy-to-identify population at risk of PsA. The prevalence of PsA has been estimated to be between 6% and 42% for this population [4] , and around 70% of PsA cases are preceded by psoriasis onset [5] . A systematic review and meta-analysis estimated an overall prevalence of undiagnosed PsA among psoriasis patients of 15.5% [6] . Consequently, dermatologists may be well placed to implement screening. However, making a diagnosis of PsA requires a detailed musculoskeletal examination, typically by a rheumatologist. Given this, several self-administered screening questionnaires to identify patients with PsA have been developed and validated for use prior to the more costly and intensive diagnostic procedures [710] . The Toronto Psoriatic Arthritis Screening (ToPAS) tool was validated in the general and psoriasis populations [7] . The Psoriasis Epidemiology Screening Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE) and the Early Psoriatic Arthritis Screening Questionnaire (EARP) follow a similar questionnaire structure and have all been validated for patients with psoriasis [810] . Screening tools for PsA have been tested in different settings, providing a vast array of accuracy estimates. Consensus regarding the best alternative is yet to be reached.
Although several studies have evaluated the screening accuracy for these tests, this information has not been systematically reviewed. The objective of this literature review is to synthesize the available evidence and obtain pooled sensitivity and specificity estimates for each tool. It also seeks to characterize the potential factors that might affect test accuracy.
Methods

Data sources and search strategies
A systematic review of electronic databases was conducted to identify studies that evaluated self-administered screening tools for PsA. We searched MEDLINE, Excerpta Medical Database, the Cochrane Central Register of Controlled Trials and Web of Science, between database inception and 8 January 2018. Search terms combined MeSH, Embase subject headings (Emtree) and keywords for PsA, screening and PsA screening tools. We also searched the reference lists of the included studies. No electronic search filters for date or language were used. For search strategies see supplementary data, electronic search strategies section, available at Rheumatology online. Ethics approval was not required to conduct this study.
Eligibility criteria
We included any study that presented accuracy estimates (sensitivity and specificity) for self-administered PsA screening tools or sufficient data to calculate the sensitivity and specificity. No restriction was applied to the study design or the type of screening tool (paper or electronicbased). Due to the lack of a specific PsA gold standard, any reference test was included. While our primary population of interest was patients with psoriasis, we also included studies where not all patients had psoriasis for consideration in secondary analyses. Studies were excluded if at least one of the following criterion was met: population was not screened for PsA; the study was not focused on screening tools (i.e. diagnostic testing); accuracy data were not reported (or could not be estimated); the screening tool was not self-administered; or reported duplicate data. The search results were screened first by title/abstract, then the full text by two independent reviewers (N.I. and V.D.). Any article that either reviewer included at the title/abstract review stage was included for full-text review. Disagreements at the full-text stage were settled by discussion until a consensus was reached by the two reviewers.
Data extraction and quality assessment
We extracted study characteristics including the author, year, country, sample size, setting, reference test, screening tool, test cut-off, PsA prevalence and psoriasis prevalence. The outcomes of interest were sensitivity and specificity, which were extracted or calculated from available data. Authors were contacted if further information was required. Quality assessment was conducted in duplicate (N.I. and V.D.) using the QUADAS-2 tool [11] , where four domains were evaluated: patient selection, index test, reference standard, and flow and timing. Each domain was assessed for risk of bias (low, unclear or high) [11] . Studies with low risk of bias across all QUADAS-2 domains were deemed as high-quality evidence for further stratified analyses.
Populations of interest
For the base case, we pooled estimates of full-text studies with 100% psoriasis prevalence that used the same cutoffs for the same screening tools. A sensitivity analysis was conducted to assess the pooled estimates after including data from abstracts. A second sensitivity analysis pooled full-text studies with any psoriasis prevalence level. Finally, we stratified based on study quality to compare the high-quality evidence estimates vs the base case. Meta-analyses were conducted only for screening tools with at least four observations.
Data synthesis
Sensitivity and specificity estimates were estimated jointly to appropriately account for their paired nature [12] . Toolspecific estimates (sensitivity and specificity) were plotted on a receiving operating characteristic space (sensitivity vs 1 specificity). This 2D space represents the trade-off between sensitivity and specificity and allows the estimation of 95% confidence ellipses [13] . The meta-analysis was conducted with a bivariate random effects model [12] . Individual studies, weighted by study size, were plotted in a summary receiving operating characteristic space with a 95% confidence regions. Forest plots and tabulations were generated to summarize the studies included in the meta-analysis. The studies that did not provide sufficient input for a meta-analysis were synthesized narratively.
The DORs were pooled to evaluate between-study heterogeneity. These were estimated using the 2Â2 contingency tables and were then transformed to the logarithm scale to estimate their standard errors. After conducting pooled analyses for the DORs per screening tool, the I 2 statistic was estimated to determine the degree of heterogeneity.
Meta-regression
A linear regression of the logarithm of the Diagnostic Odds Ratio (DOR) vs test cut-offs was run to determine whether the DORs varied across positivity thresholds [14] . We controlled for each screening tool using a categorical variable, where the EARP was set as the reference, i.e. DOR = b 0 + b 1 * tool + b 2 * cut-off. We then conducted a meta-regression to evaluate whether study characteristics were associated with the diagnostic accuracy of the screening tests. [10, 26, 43, 44] .
Supplementary Table S1 , available at Rheumatology online, summarizes the screening tools, diagnostic criteria and accuracy estimates. Overall, 104 separate sensitivity and specificity estimates were reported, and 21 (50%) studies evaluated a single screening tool at a single cut-off. A total of 14 different screening tools were identified in the review. The PASE was evaluated most frequently (n = 28), followed by PEST (n = 19), and ToPAS and EARP (n = 10 each). The Psoriasis and Arthritis Screening Questtionaire (PASQ), ePASQ, ToPAS II, COmparisoN of ThrEe Screening Tools in Psoriatic Arthritis (CONTEST) and Center of Excellence for Psoriasis and Psoriatic Arthritis (CEPPA) were evaluated eight, seven, six, six and five times, respectively. There was not enough information to meta-analyse these screening tools for a specific cut-off value. Some tools were only registered once [Glasgow Ultrasound Enthesitis Scoring System (GUESS), German Psoriasis Arthritis Diagnostic (GEPARD), Fluorescence optical imaging (FOI), PASE-2 and The Siriraj Psoriatic Arthritis Screening Tool]. Questionnaire-based screening tools reported a completion time between 5 and 10 min [8, 10] . Diagnostic criteria varied across studies, as a third of the studies (n = 14) used a rheumatologist evaluation along with the CASPAR criteria to establish a diagnosis [1720, 24, 30, 33, 34, 37, 39, 47, 48, 51, 52] , and four (9.5%) used the Moll Wright criteria alongside a clinical evaluation [8, 23, 38, 43] . Finally, a single study (2.4%) used ultrasound along with a clinical evaluation [35] , and 21 (19%) used either clinical or rheumatologic assessment alone. Table 2 includes details of the meta-analysed tools. The PEST, PASE, EARP and ToPAS include 5, 15, 10 and 12 items or questions, respectively. They are mainly focused towards physical disability, and skin and joint symptoms. All of them include questions related to swollen joints and associated pain. The ToPAS and PEST include items related to affected nails and toes. They also include an item about previously diagnosed PsA. The PASE and the EARP refer to swollen fingers as 'sausage-shaped' for easier understanding. The PEST and EARP include an item related to swollen ankles. The ToPAS is the only tool that includes items directly related to psoriasis of the skin. The other tools were validated for patients with psoriasis, rendering the skin-related items redundant. The ToPAS and the PEST include images that help complete the questionnaires; a mannequin is available with the PEST for the patients to highlight which joints are affected. The ToPAS includes skin and nail images to assist patients in identifying potential symptoms.
The quality assessment is summarized in supplementary Table S2 , available at Rheumatology online. Only full texts [27] were assessed at this stage. Overall, 10 (37%) studies were identified as high quality or low risk of bias across the four domains evaluated by the QUADAS-2 tool. We identified 10 (37%) studies that failed to state whether the index test was blinded to the reference test, and 10 that did not explain whether the reference test was Have you ever had a skin rash consisting of red AND silvery-white scaly areas particularly on the elbows, knees or scalp as shown in Fig. 1 
My joints hurt
Have you taken an anti-inflammatory more than twice a week for joint pain in the last 3 months?
Have you ever noticed any of these changes in your fingernails: pits in the nails as shown in Fig. 2 ; lifting of the nail from the nail bed as shown in Fig. 3 My back hurts Have you ever had back pain lasting at least 3 months that was not injury related?
I am unable to be as active as I used to be
Have you ever had a skin rash on any part of your body at the same time as joint pain, joint-stiffness or swollen red joints?
Have you had a finger or toe that was completely swollen and painful for no apparent reason?
I feel stiff for more than 2 h after waking up in the morning Do your feet or ankles hurt?
Have you ever seen a doctor about any joint pain?
The morning is the worst time of day for me
Have you ever been diagnosed with any form of arthritis other than PsA?
It takes me a few minutes to get moving to the best of my ability, blinded to the index test. These were rated as having unclear risk of bias. No studies were ranked with high risk of bias for these domains as no study clearly failed to blind the test results. Furthermore, eight (29.6%) studies had an unknown risk of bias due to the sampling procedure (not clear whether random or consecutive patients were enrolled). A third of the full-text studies (n = 9) included patients that were already diagnosed with PsA in a casecontrol study design. They were identified as having a high risk of bias and applicability concerns for the study design and patient selection category.
Head-to-head studies
A total of 17 studies evaluated and compared two or more PsA screening tools. Tinazzi et al. [10] found that the EARP was slightly better than the PASE at identifying PsA; Mishra et al. [42] compared the sensitivity and specificity of the EARP, ToPAS II, PEST and PASE. The EARP was the most sensitive and the ToPAS II the most specific. Most studies found that the questionnaire-based screening tools were very similar in terms of accuracy [31, 32, 
Meta-analyses
We included 31 different test accuracy estimates of fulltext studies with 100% psoriasis prevalence for metaanalysis. There was enough information to pool accuracy estimates for the PASE (seven and six studies with cutoffs = 44 and 47, respectively), ToPAS (five studies with cut-off = 8), PEST (eight studies with cut-off = 3) and EARP (five studies with cut-off = 3). The forest plots of these studies with their 2Â2 contingency tables can be found in Fig. 1 . The meta-analyses (base case and sensitivity analyses) are summarized in Table 3 . The EARP had the highest pooled sensitivity and specificity estimates, at 0.85 each for the base case. Sensitivity estimates for the ToPAS, PASE and PEST fluctuated between 0.65 and 0.74. Specificity estimates ranged between 0.68 and 0.83. Fig. 2 summarizes the pooled estimates with their respective 95% confidence ellipses. Fig. 3 shows the individual meta-analyses with their pooled estimates and 95% confidence ellipses. Sensitivity and specificity estimates were robust to the inclusion of data from abstracts (first sensitivity analysis) and studies with different psoriasis prevalences (second sensitivity analysis); estimates varied by at most four percentage points across all tools for both stratified analyses compared with the base case (Table 3) . Stratified metaanalyses were conducted based on study quality or risk of bias. Study quality had a minimal impact on most estimates of sensitivity or specificity (Table 3 ). The greatest difference was for the specificity with EARP, which dropped from 0.85 (95% CI: 0.610.95) when all five studies were included, to 0.78 (95% CI: 0.530.91) for the four studies rated as high quality.
Meta-regression and positivity threshold
We found substantial heterogeneity across studies after meta-analysing the diagnostic odds ratios. The I 2 estimates ranged from 76 to 90.1%. The regression and meta-regression results are available in supplementary Table S3 , available at Rheumatology online. Based on the linear regression, the DOR was not associated with the cut-off used by each tool (P = 0.657). On the other hand, the multivariate meta-regression estimated statistically significant coefficients for mean age (P = 0.004), patient-selection risk of bias (P = 0.02) and the three screening tools relative to EARP (ToPAS P = 0.01, PEST P = 0.026, PASE P = 0.002). The screening tools are expected to be less accurate as the mean age of the study population increases. The estimated DOR is reduced by 11% for each additional year. Furthermore, studies with low risk of bias in the patient selection domain of the QUADAS-2 are associated with lower test accuracy (85% smaller DOR) compared with studies with high or unclear risk of bias. Regarding screening tools, the DORs of the PEST, ToPAS and PASE are expected to be 70.3, 80.7 and 81.7% smaller compared with the EARP, respectively. Finally, the conclusions for the univariate and multivariate regressions were maintained. The setting, diagnostic criteria, test blinding risk of bias and psoriasis prevalence were not statistically significant in the individual meta-regressions or in the multivariate meta-regression.
Discussion
In this systematic review and meta-analysis, we synthesized the evidence on PsA screening and generated pooled estimates for screening tools that reported sensitivity and specificity outcomes. The pooled sensitivity and specificity for the most commonly reported questionnairebased screening tools (ToPAS, PEST, PASE and EARP) ranged between 0.65 and 0.85, and 0.68 and 0.85, respectively. The EARP was the most accurate screening tool with the highest sensitivity and specificity (0.85 each), including when only high-quality studies were included. However, further evidence and direct comparisons are required to account for the uncertainty and to determine whether the EARP's accuracy is comparably higher than that of the other questionnaire screening tools. Results were robust to the inclusion of data from abstracts and studies with different psoriasis prevalence levels. Considerable between-study heterogeneity was found for all screening tools. A multivariable meta-regression found that the mean age, psoriasis prevalence, risk of bias of patient selection and the screening tools explained some of the heterogeneity. Furthermore, a few head-tohead studies suggested that the self-administered PsA screening tools were similar to each other in terms of accuracy. Further studies could evaluate the effect of different predictors, such as disease severity, on test accuracy. This review suggests that the EARP has a slightly better accuracy than the PEST, PASE and ToPAS to screen for PsA in psoriasis patients.
Entities such as the UK National Health Service have recommended the early identification of PsA with screening questionnaires and further diagnostic testing to slow disease progression [53] . Ever since, several efforts have been directed towards creating screening tools that would allow PsA patients with psoriasis to be identified in secondary care settings (specifically dermatology and/or rheumatology) [710] . This review creates a novel synthesis of the available information and evaluates the evidence of both new interventions and further validations of already popular screening tools. It provides evidence that the meta-analysed questionnaire screening tools are not only similar to each other in terms of structure, time to complete (between 510 min) [8, 10] and validation setting, but also in terms of accuracy. Other questionnaire tools such as the CEPPA, CONTEST and GEPARD have tried to put together different parts of other questionnaires to create a new and improved version [20, 27, 35] . However, separate studies do not appear to present compelling evidence of superior screening accuracy. On the other hand, biomarker testing for PsA screening is becoming an increasingly popular field of study [54, 55] . These studies were not included in this review as they are not self-administered screening tests. The comparison and feasibility of biomarker vs questionnaire screening for PsA or the combining of the two is yet to be evaluated.
It has been previously concluded that PsA screening tests usually have low specificity because of the heterogeneous nature of the disease [20] . Similar musculoskeletal disorders, such as OA, might be identified as false-positive cases [50] . The reason why specificity fluctuates considerably across screening tools and studies in this review could be explained by different prevalence levels of similar musculoskeletal disease within the study populations. These questionnaires prioritize the identification of undiagnosed PsA before trying to differentiate it from similar conditions. Generally, because screening tests seek to rule out disease, they are expected to be highly sensitive [56] . If the follow-up tests are not too invasive and/or expensive, false positives are often preferred to false negatives. The costs and benefits of sensitivity vs specificity could be compared using costeffectiveness modelling.
This review faced some limitations. The meta-analysis estimated high heterogeneity for each screening tool. The predictor variables evaluated through meta-regression accounted for some between-study variation, but some predictors were not statistically significant. This could be due to the low statistical power of the meta-regression. Furthermore, there are additional factors that might explain this heterogeneity. Mease et al. [41] concluded that interpreting the findings of several PsA screening studies was problematic due to differences in study population characteristics, such as psoriasis severity [Psoriasis Area and Severity Index (PASI) score], treatment, and duration of PsA. Eder et al. [57] also concluded that severe cases of psoriasis (PASI score >20) have been associated with an increased risk of PsA. Although we extracted PASI, only 18 studies reported it. The reported ranges and measures of spread suggest that only the study conducted by Chamurlieva et al. [17] might have included a significant proportion of severe PASI cases (mean = 15.36). If the studies had reported PASI consistently, we could have evaluated this as an additional predictor. Additionally, PsA severity is expected to have a considerable effect on test accuracy. Severe PsA cases are expected to be easier to identify [58] . That is why including already diagnosed PsA cases will most likely bias the accuracy estimates. These patients are expected to have more severe disease and be easier to identify. Additionally, evaluating the difference between primary vs secondary dermatology clinics could potentially explain some of the heterogeneity. However, this sub-analysis could not be conducted due to a lack of studies. Consistency across studies needs to be maintained if further analyses are to compare PsA screening tools. Finally, improved reporting standards or additional and larger head-to-head studies could reduce the heterogeneity of these pooled estimates.
It is not entirely clear whether the EARP is the most accurate tool due to its increased capacity to identify early disease, the low cut-off or the lack of a larger head-to-head study that compares the four tools among the same cohort. Regarding its structure, the EARP has a few characteristics and items that might explain its higher accuracy. Unlike the other tools, the EARP asks specifically about pain and swelling of joints that are often affected by PsA, such as the Achilles tendon, wrists, hips, feet, fingers and ankles. While the PEST, PASE and ToPAS ask more generally about finger or joint pain (i.e. Have you ever had a swollen joint?-PEST; My joints hurt-PASE; Have you ever had a sausageshaped swollen finger . . .-ToPAS), the EARP has specific questions for regularly affected joints by PsA (i.e. Do your fingers and wrists hurt? Do your elbow or hips hurt?). On the other hand, the low 3/10 cut-off might also explain why the EARP is more sensitive. However, a low cut-off usually translates to reduced specificity. Finally, obtaining head-to-head evidence could allow for direct comparisons and organizing tools into a relative ranking to inform decision makers. Considering that this evidence is difficult and costly to obtain, diagnostic network metaanalyses are useful to evaluate indirect comparisons with the limited available evidence [59] .
The results of this first literature review of PsA screening provide a foundation for further research. After summarizing the available information and obtaining pooled clinical efficacy estimates, it is necessary to further evaluate the factors that might explain the heterogeneity. However, PsA screening is but the first step in the treatment pathway meant to slow down disease progression and improve health outcomes. To understand the effect of investing in a systematic PsA screening program, a healthcare system must take into account the entire diagnostic and treatment pathway. The information on PsA screening is only valuable if it has the potential to modify clinical practice and improve health outcomes. Therefore, although this review concludes that these tools have a moderate capability to identify PsA, it is imperative to determine whether implementing screening procedures (and diagnostic and treatment follow-ups) are cost-effective. A cost-effectiveness analysis has the capability to evaluate the value of PsA screening, taking into account the uncertainty around test accuracy and different parameters that might have an impact on   FIG. 3 Tool-specific bivariate meta-analyses for full-text studies with psoriasis patients only HSROC: hierarchical summary receiver operating characteristic; PASE: Psoriatic Arthritis Screening and Evaluation; PEST: Psoriasis Epidemiology Screening Tool; ToPAS: Toronto Psoriatic Arthritis Screening Tool; EARP: Early Psoriatic Arthritis Screening Questionnaire.
screening accuracy such as PsA severity and disease progression. An economic evaluation would be able to use these pooled estimates and raw data from the identified individual studies and quantify the trade-off between sensitivity and specificity, and determine the threshold at which a screening tool would be cost-effective for implementation.
